Figure 4 | Scientific Reports

Figure 4

From: CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor

Figure 4

p53 WT cells are more sensitive to mocetinostat. A549 p53+/+ and p53−/− cells were treated with vehicle or mocetinostat (1 µM) for 24 h. Lysates were immunoblotted for the indicated proteins (representative images of three independent experiments) (A). mRNA was qPCR analyzed for the indicated gene. Average (from three experiments) relative mRNA is presented with SD indicated. Statistical differences are indicated (*p < 0.05, **p < 0.01, ***p < 0.001) (B). (C) A549 p53+/+ and p53−/− cells were treated with vehicle or mocetinostat (1 µM) for 72 h and then analyzed for sub-G1 cells. % sub-G1 cells are presented with SD indicated. Statistical difference is indicated (*p < 0.05). (D). A549 p53+/+ and p53−/− cells were treated with vehicle or the indicated doses of mocetinostat (1 µM) for 72 h and then analyzed with MTT assay. Average (8 replicates) relative MTT absorbance is presented with SD indicated.

Back to article page